Journal NET

What treatment advancements occurred in the 2010s for pancreatic neuroendocrine tumors (PNETs)?

• Introduction of surgery only

• Approval of everolimus and lanreotide

• Focused on radiation therapy

• •Use of chemotherapy alone

What was the primary endpoint in the study?

• Progression-Free Survival (PFS)

• Overall Survival (OS)

• Complete Response (CR)

• Disease-free survival

Why was overall survival (OS) not the focus of the study?

• Focus on faster disease progression

• Cross-over between treatment arms

• No access to OS data

• Short follow-up duration

Which of the following was a limitation of the study?

• High representation of racial diversity

• Statistically significant overall survival benefit

• High rates of side effects and limited generalizability

• Small sample size

What was a strength of the study?

• Low dropout rates

• Short follow-up duration

• Double-blind design

• Focused on early-stage neuroendocrine tumors